Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 11/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 9/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 9/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.46 |
| ▸ | NQO2 | P16083 | 2/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2637323 | 1.00 | CYP19A1 (0.54) | CYP19A1APPMAPTCYP1A1CYP1B1 | |
| SCHEMBL13003198 | 0.87 | CYP19A1 (0.60) | CYP19A1APPMAPTCYP1A1CYP1B1 | |
| SCHEMBL13018885 | 0.81 | CYP19A1 (0.79) | CYP19A1APPMAPTCYP1A1CYP1B1 | |
| SCHEMBL3765052 | 0.81 | CYP19A1 (0.79) | CYP19A1APPMAPTCYP1A1CYP1B1 | |
| SCHEMBL2636924 | 0.75 | APP (0.38) | APPMAPTCYP1A1CYP1B1CYP1A2 | |
| SCHEMBL3760090 | 0.75 | APP (0.38) | APPMAPTCYP1A1CYP1B1CYP1A2 | |
| SCHEMBL3760089 | 0.75 | APP (0.38) | APPMAPTCYP1A1CYP1B1CYP1A2 | |
| SCHEMBL13059996 | 0.74 | CYP19A1 (0.68) | CYP19A1APPMAPTCYP1A1CYP1B1 | |
| SCHEMBL2636930 | 0.74 | APP (0.36) | APPMAPTCYP1A1CYP1B1CYP1A2 | |
| SCHEMBL12555831 | 0.72 | CYP19A1 (0.65) | CYP19A1APPMAPTCYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2437792-B1 | IMAGING OF MYELIN BASIC PROTEIN | GEN ELECTRIC (US) | 2015-10-21 | — | — | EP | disclosed |
| EP-2437792-A2 | IMAGING OF MYELIN BASIC PROTEIN | General Electric Company (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20100310456-A1 | IMAGING OF MYELIN BASIC PROTEIN | GENERAL ELECTRIC COMPANY (US) | 2010-12-09 | — | — | US | disclosed |
| WO-2010141704-A2 | IMAGING OF MYELIN BASIC PROTEIN | GENERAL ELECTRIC COMPANY (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310456-A1 | IMAGING OF MYELIN BASIC PROTEIN | MAG, PMP22, MYT1 | CYP19A1 4885/4885APP 1205/4885MAPT 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.